TheEdgeResearch
Home / Stocks / CLGN

CollPlant Biotechnologies Ltd. (CLGN)

NASDAQ Healthcare Biotechnology
$0.30 ▲ +0.61%
Market Cap
$3.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.68
52-Wk Range
0.27-3.18
CEO
Yehiel Tal
Country
IL
Currency
USD

CollPlant Biotechnologies Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Rehovot, TA, IL. The stock last traded at $0.30, up 0.61% on the session, giving a market capitalisation of $3.8M. On trailing twelve-month figures it carries a trailing P/E of -0.29, a net margin of -3376.3%. Its beta of 0.68 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.29
Price / Sales
9.89
Price / Book
0.84
EV / EBITDA
-0.19
Gross margin
-319.3%
Operating margin
-3329.0%
Net margin
-3376.3%
Return on equity
Debt / equity
0.54
Current ratio
2.27
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
39
IPO date
2018-01-31
Headquarters
Rehovot, TA, IL
About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.

Comparable companies

CollPlant Biotechnologies Ltd. is most often compared with the following Healthcare names:

CVKDENLVKLTOMTVANRSNNRXSRLYBSONNTAOXXCUR
More research on CLGN
CLGN technical analysis CLGN TheEdge Score Compare against peers
Open full interactive analysis & DCF →